BioArctic (BIOA-B.ST) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Total funding raised: $25M

Market Cap: $3.2BPipeline: 1 drugPatents: 2Founded: 2003HQ: Stockholm, Sweden

Sector Ranking#59 in Biologics / Biosimilars #5 in Neuroscience & CNS

Overview

BioArctic is a research-driven biopharma company with a mission to develop transformative treatments for neurodegenerative diseases. Its strategic partnership with Eisai led to the landmark approval and commercialization of lecanemab for Alzheimer's, providing a foundational revenue stream. The company's core strategy is to leverage its proprietary BrainTransporter™ platform to build a diversified pipeline of next-generation biologics for Parkinson's and ALS, while continuing to advance its Alzheimer's franchise.

Alzheimer's DiseaseParkinson's DiseaseALS

Technology Platform

Proprietary BrainTransporter™ technology platform designed to engineer bispecific antibodies that utilize receptor-mediated transcytosis to actively transport therapeutic antibodies across the blood-brain barrier.

Pipeline

1

1 drug in pipeline

Drug	Indication	Stage	Watch
exidavnemab + Placebo Comparator	Parkinson Disease	Phase 2

Funding History

3

Total raised:$25M

Grant$5MSwedish Research CouncilJun 15, 2019

IPOUndisclosedUndisclosedDec 8, 2017

IPO$20MUndisclosedJun 15, 2017

Opportunities

The successful launch of lecanemab has opened a multi-billion dollar market for disease-modifying Alzheimer's therapies, providing BioArctic with a robust royalty stream.

The proprietary BrainTransporter™ platform presents a major opportunity to disrupt treatment in Parkinson's and other CNS disorders by solving the critical drug delivery challenge, potentially creating best-in-class therapeutics.

Risk Factors

Revenue is heavily concentrated on the commercial success of a single partnered product (lecanemab).

The proprietary pipeline, led by BAN2802, faces inherent clinical development and regulatory risks, and the alpha-synuclein target in Parkinson's remains unproven.

The company also operates in intensely competitive therapeutic areas with rapidly evolving scientific and commercial landscapes.

Competitive Landscape

In Alzheimer's, BioArctic (via Eisai) competes directly with Lilly's donanemab. In Parkinson's, its BrainTransporter™-enabled BAN2802 will compete against other alpha-synuclein-targeting antibodies from companies like Prothena and UCB. The core platform also faces competition from other BBB shuttle technologies, such as Denali Therapeutics' TV platform.